These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
corona_manuscript_ChemRxiv.pdf (1.08 MB)
Gold Metallodrugs to Fight the Corona Virus: Inhibitory Effects on the SpikeACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 16.06.2020 and posted on 18.06.2020by Maria Gil-Moles, Uttara Basu, Rolf Büssing, Henrik Hoffmeister, Sebastian Türck, Agnieszka Varchmin, Ingo Ott
Gold complexes have a long tradition in medicine and for many examples antirheumatic,
anticancer or anti-infective effects have been confirmed. Here we evaluated the lead
compound Auranofin and five selected gold organometallics as inhibitors of two relevant drug
targets of severe acute respiratory syndrome coronaviruses (SARS-CoV). The gold
metallodrugs were effective inhibitors of the interaction of the SARS-CoV-2 spike protein with
the angiotensin converting enzyme 2 (ACE2) host receptor and might thus interfere with the
viral entry process. The gold metallodrugs were also efficient inhibitors of the SARS-CoV-1
papain-like protease (PLpro), which is a key enzyme in the viral replication. Taken together,
the results of this pilot study suggest further evaluation of gold complexes as SARS-CoV